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RESUMEN
Se hacen reaccionar 4-(fenil o  p-metoxifenil)-6-tioxo-1,6-
dihidro-2,3’-bipiridin-5-carbonitrilos 1a,b con yodometano 
y a continuación con hidrato de hidrazina, o bien 
directamente con hidrato de hidrazina, para obtener las 
correspondientes 6-piridin-3-il-1H-pirazolo[3,4-b]piridin-
3-aminas  4a,b. Los compuestos 4a,b se usan como 
productos de partida en el presente estudio, reaccionando 
con ácido nitroso para dar las correspondientes sales 
de diazonio 5a,b. Estos últimos compuestos se hacen 
reaccionar seguidamente por acoplamiento con diversos 
reactivos que contienen grupos –CH2- activos, 6, 9a,b, 
11a,b, 14, 17 y 19, con la intención de sintetizar diversos 
derivados de pirido[2’,3’:3,4]pirazolo[5,1-c][1,2,4]triazinas 
8a,b, 10a-d, 12a,b, 15a,b, 18a,b, y 20b. Las estructuras de 
todos los nuevos compuestos heterocíclicos sintetizados 
se determinan a partir de los datos de los análisis 
elementales, IR, 1H RMN y espectrometría de masas. 
Todos los nuevos compuestos heterocíclicos sintetizados 
se ensayan como reactivos anti-Alzheimer y anti-cox2, 
exhibiendo resultados prometedores.
Palabras clave: Yodometano, hidrato de hidrazina, 
bipiridin-5-carbonitrilos, pirazolopiridin-3-aminas, 
piridopirazolotriazinas.
SUMMARY
4-(Phenyl or  p-methoxyphenyl)-6-thioxo-1,6-dihydro-
2,3’-bipyridine-5-carbonitriles 1a,b reacted with 
either iodomethane followed by hydrazine hydrate or 
hydrazine hydrate directly to give the corresponding 
6-pyridin-3-yl-1H-pyrazolo[3,4-b]pyridin-3-amines  4a,b. 
Compounds 4a,b were used as the starting materials 
of the present study, they reacted with nitrous acid 
to give the corresponding diazonium salts 5a,b. The 
latter compounds reacted further via their coupling with 
several active –CH2- containing reagents 6, 9a,b, 11a,b, 
14, 17 and 19 aiming to synthesize several derivatives of 
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pyrido[2’,3’:3,4]pyrazolo[5,1-c][1,2,4]triazines 8a,b, 10a-d, 
12a,b, 15a,b, 18a,b, and 20b. The structures of all newly 
synthesized heterocyclic compounds were elucidated by 
considering the data of elemental analyses, IR, 1H NMR 
and mass spectrometry. All newly synthesized heterocyclic 
compounds were tested as anti-Alzheimer and anti-cox2 
reagents and exhibit promising results.
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RESUM
Es fa reaccionar 4-(fenil o  p-metoxifenil)-6-tioxo-1,6-
dihidro-2,3’-bipiridin-5-carbonitrils 1a,b amb iodometà 
seguit d’hidrat d’hidrazina o bé directament amb hidrat 
d’hidrazina per donar les corresponents 6-piridin-3-il-1H-
pirazolo[3,4-b]piridin-3-amines  4a,b. Els compostos 4a,b 
s’empren com a productes de partida en el present estudi, 
reaccionant amb àcid nitrós per donar les corresponents 
sals de diazoni 5a,b. Aquests darrers compostos es fan 
reaccionar tot seguit via el seu acoblament amb diversos 
reactius que contenen grups –CH2- actius, 6, 9a,b, 11a,b, 
14, 17 i 19, amb la intenció de sintetitzar diversos derivats 
de pirido[2’,3’:3,4]pirazolo[5,1-c][1,2,4]triazines 8a,b, 10a-
d, 12a,b, 15a,b, 18a,b, i 20b. Les estructures de tots els 
nous compostos heterocíclics sintetitzats es determinen a 
partir de les dades dels anàlisis elementals, IR, 1H RMN 
i espectrometria de masses. Tots els nous compostos 
heterocíclics sintetitzats s’assagen com a reactius anti-
Alzheimer i anti-cox2, exhibint resultats prometedors.
Mots clau: Iodometà, hidrat d’hidrazina, 
bipiridin-5-carbonitrils, pirazolopiridin-3-amines, 
piridopirazolotriazines
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INTRODUCTION
In conjunction with our previous work1-20 and the reported 
biological activities of pyrazolopyridines as Potent and 
Selective Inhibitors of Glycogen Synthase Kinase-321-23; 
Cyclin-Dependent Kinases: Highly 
Potent 2,6-Difluorophenacyl Analogues24, A1-Adenosine 
Receptor (A1AR) Ligands25 and pyridopyrazolotriazines 
are applied as antimicrobial agents7 stimulated our interest 
to synthesize, characterize and investigate of several 
derivatives of these ring system. Our target here is the 
synthesis and study of the biological importance of each 
of pyrazolo[3,4-b]pyridin-3-amines and pyrido[2’,3’:3,4]
pyrazolo[5,1-c][1,2,4]triazines. 
RESULTS AND DISCUSSION
It has been found that each of 4-phenyl-6-thioxo-1,6-dihydro-
2,3’-bipyridine-5-carbonitrile and 4-(4-methoxyphenyl)-
6-thioxo-1,6-dihydro-2,3’-bipyridine-5-carbonitrile 
1a,b20 reacted with iodomethane in methanolic sodium 
methoxide under stirring at room temperature to give the 
corresponding 2-methylthio derivatives 3a,b respectively. 
Compounds 3a,b reacted with hydrazine hydrate under 
reflux to give the corresponding 4a,b respectively. An 
authentic samples of 4a,b obtained via the reaction of 
1a,b with hydrazine hydrate under reflux. It is important to 
report here that the reaction of 1a,b with hydrazine hydrate 
proceeded through the removing of H2S molecule while the 
reaction of 3a,b with hydrazine hydrate proceeded via the 
methyl mercaptan removal. The IR (cm-1) of 3a,b showed 
the absorption bands of CN function which disappeared in 
case of 4a,b and instead the newly formed NH2 function 
was detected. The mass spectra of each of 3a,b and 
4a,b gave the parent peaks at m/z = 303, 333, 287 and 
317 which corresponding to the molecular weights of 
their assigned structures respectively. Other peaks for 
compounds 3a,b and 4a,b were detected and these peaks 
gave further elucidation for their structures (cf. Exp. Part 
and Scheme 1).
The position and chemical reactivity of NH2 in 4a,b was 
investigated via their reaction with nitrous acid to give the 
corresponding diazonium salts 5a,b respectively. 
Compound 5a reacted with ethyl cyanoacetate (6) in 
ethanol containing sodium acetate under stirring to 
affored the corresponding 7a 1H-NMR revaled the signals 
of –COOCH2CH3  and two NH protons and IR shows 
the absorption bands of CN and ester groups. Heating 
compound 7a in ethanol containing piperidine under 
reflux afforded compound 8a rather than 8’a. The reaction 
proceeded through the addition on the CN function to give 
8a or through ethanol molecule removal to give 8’a:  
The IR spectra of the reaction product 8a didn’t show 
the absorption band of CN function and instead the 
absorption bands of NH2 function was detected and 
this corresponding to the compound 8a rather than 8’a. 
In contrast behavior compound 5b reacted with ethyl 
cyanoacetate (6) either in ethanol containing sod.acetate 
or in EtOH/pip to afford directly compound 8b rather than 
8b’. Furthermore, their mass spectra gave the m/z= 411 
and 441 which corresponding to the molecular weights of 
8a,b respectively. 
In a similar behavior, Compounds 5a, b reacted with each 
of ethyl 3-oxobutanoate (9a) to give 10a,b rather than 
10’a,b and pentan-2,4-dione (9b) to give 10c,d under the 
above-mentioned experimental conditions: 
Scheme 1
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The mass spectra of compounds 10a-d gave m/z=410 and 
440, 380 and 410 which corresponding to the molecular 
weights of 10a-d respectively.  The structures of 10a-d 
were further confirmed via 1H NMR spectral data of 10b,d 
as the typical examples which revealed the signals of 
–COOCH2CH3 protons in 10b and COCH3 protons of 10d 
(cf. Exp. Part). The other analogs 11a, b coupled with each 
of 5a,b under the same above-mentioned experimental 
conditions to give the corresponding triazines 12a, b 
respectively. 
The formation of compounds 12a,b proceeded through de 
hydrochlorination with intramolecular cyclization via NH 
addition on CN function in case of 11a and removal of H2S 
in case of 11b .
The IR spectrum of 12a,b indicated the presence of CN 
group. Further more their mass spectra gave m/z= 364 
and 394 which corresponding to the molecular weights of 
12a,b respectively. 
Similarly, compounds 5a,b reacted with ethyl 3-oxo-3-
phenylpropanoate (14) which gave the reaction product 
15a,b rather than 16a,b.       
The rejection of 16a,b depends on the appearance of the 
band at 1732 for CO ester in IR and detection of the signals 
1.175 (t, 3H, CH2CH3), 4.26 (q, 2H, CH2CH3) for compound 
15a (cf. Exp. part).
The work extended to investigate further the reactivity 
of both chlorine atom and NH-pyrazole in compounds 
5a,b. It has been found that compounds 5a,b reacted 
with diethylmalonate (17) to give the reaction products 
18a,b which formed via the dehydrochlorination followed 
by intramolecular cyclization via removal of ethanol. The 
structure of compounds 18a,b was confirmed based on 
elemental and spectral data(cf. Exp. part).
Finally compound 5b reacted with 3(4-Chlorophenyl)-3-
oxopropanenitrile (19) to give the reaction product 20b 
rather then compound 21b. Formula of 20b established by 
considering the data of  IR, elemental analysis and mass 
spectrum (cf. Exp. part) on such data we reject formula 
21b.
Biological Evaluation
Anti-Alzheimer activity 
Compounds 5a,b reacted with several reagents to give 
compounds 7a, 8b, 10a-d, 12a,b, 15a,b, 18a,b, and 20b. 
For series a,b the substituted pyrazole derivatives have 
potent activities where the compounds arranged according 
to descending order of activity 3a, 4a, 10c, 12a, 7a, 5a, 
18a, 10a, 15a, 4b, 18b, 12b, 10b, 10d, 3b, 8b, 20b, 1b, 
1a, 15b (See Figure 1).
Figure 1
Its worth to mention that as the activity increases both 
the pharmacokinetics and pharmacodynamics properties 
greatly improved to be directed towards a good bioavailability 
drug profiles (See Figures 2, 3). 
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Figure 2
Figure 3
Structural Activity Relationship of anti-Alzheimer 
activity
Generally for compounds a we note that the phenyl moiety 
provides the highest Anti-Alzheimer activity from phenyl-
p-methoxy. Thus, we can conclude that the p-methoxy 
group has no effect.
Anti-COx-2 activity
For series a have potent activities where the compounds 
arranged according to descending order of activity 3a, 
4a and series b compounds showed moderate potent 
activities and the activity in descending order  is 20b, 10d, 
18b, 1b, (12b, 15b), (4b, 8b),  10b, 3b (See figure 4).
Figures 4
Structural Activity Relationship for anti-COx2 
Generally for compounds b the p-methoxyphenyl moiety 
provides the highest activity. Acute toxicity of both 
compounds a,b illustrated by figures 5  
Figure 5
ExPERIMENTAL
All melting points were uncorrected. I.R. (KBr discs) 
spectra were recorded on a Shimadzu FTIR-8201PC 
Spectrophotometer. 1H-NMR spectra were recorded on a 
Varian Mercury 300 MHz., and a Varian Gemini 200 MHz. 
spectrometers using TMS as an internal standard and 
CDCl3, DMSO-d6, and (CD3)2CO as solvents. Chemical 
shifts were expressed as δ (ppm) units. Mass spectra 
were recorded on Shimadzu GCMS-QP1000EX using an 
inlet type at 70 eV. The Micro analytical Center of Cairo 
University performed the microanalyses.
Synthesis of 3a,b
A solution of each of 1a,b (0.29g and 0.32g 1mmole) and 
methyl iodide (2) (0.3g, 2mmole) in sodium methoxide 
(prepared from 0.14 g of sodium and methanol 25 mL) was 
stirring at room temperature for 15 minutes. The formed 
precipitate was collected by filtration, washed with water 
and crystallized from the proper solvent to give 3a, b 
respectively.
6-(Methylthio)-4-phenyl-2,3’-bipyridine-5-carbonitrile(3a): 
pale yellow crystals (87%), m.p = 212 °C; IR υ(cm-1): 3045 
(C-H, aromatic), 2211 (CN); MS (m/z): 303 ( M+, 24.6% 
which corresponding to the molecular formula C18H13N3S of 
the assigned structure), 302 (M+-H, 100%), 275 (M+-CN, 2H, 
10%), 256 (M+ -SCH3);  Anal., for C18H13N3S (303), Calcd./
Found (%):C(71.26/71.30) H(4.32/4.36) N(13.85/13.89) 
S(10.57/10.60).
4-(4-Methoxyphenyl)-6-(methylthio)-2,3’-bipyridine-
5-carbonitrile (3b): Pale yellow crystals (90%), m.p = 210 
°C; MS (m/z): 333 ( M+, 31.6% which corresponding to the 
molecular formula C19H15N3OS of the assigned structure), 
332 (M+-H, 100%); Anal., for C19H15N3OS (333), Calcd./
Found (%):C(68.45/68.48) H(4.53/4.57) N(12.60/12.63) 
S(9.62/9.66).
Synthesis of 4a,b
Method A: A solution of each of 1a,b (0.29g and 0.32g 
1mmole) in hydrazine hydrate (10 mL), ethanol (20 mL) and 
pyridine (10mL) heated under reflux for 96hrs. The excess 
solvent evaporated, and the solid formed after cooling 
collected by filtration, dried and recrystallized from ethanol 
to give the corresponding 4a,b respectively.. 
Method B: A solution of each of 3a, b (0.303g and 0.333g 
1mmole) in hydrazine hydrate (10 mL) in ethanol (20 
mL) heated under reflux for 96hrs. The excess solvent 
evaporated, and the solid formed after cooling was 
collected by filtration, dried and recrystallized from ethanol 
to give the corresponding 4a,b respectively.
4-Phenyl-6-pyridin-3-yl-1H-pyrazolo[3,4-b]pyridin-
3-amine(4a): yellow crystals, (72%), m.p =240 C°, IR 
υ(cm-1): 3429.5, 3293.0 (NH2), 3202 (NH), 3035 (C-H, 
aromatic); MS (m/z): 287 ( M+, 100% which corresponding 
to the molecular formula C17H13N5 of the assigned structure), 
286 (M+-H, 52.1%), 285 (M+-2H, 20.8%), 271 (M+ -NH2, 
7.6%);1H-NMR (δppm)(DMSO); 4.586 (s, 2H, /NH2); 7.514-
8.658(m, 9H, Ar and pyridinyl H’s); 9.357 (s, 1H, C5(H)); and 
12.443(s, 1H, NH); Anal., for C17H13N5 (287) Calcd./Found 
(%):C(71.06/71.10) H(4.56/4.59) N(24.37/24.40).
4-(4-Methoxyphenyl)-6-pyridin-3-yl-1H-pyrazolo[3,4-b]
pyridin-3-amine(4b): Yellow crystals, (69%), m.p =248 C°, 
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IR υ(cm-1): 3417.6, 3293.7 (NH2), 3190.9 (NH), 3133.4 (C-H, 
aromatic); MS (m/z): 317 ( M+, 100% which corresponding to 
the molecular formula C18H15N5O of the assigned structure), 
316 (M+-H, 39.1%), 315 (M+-2H, 3.2%), 301 (M+ -NH2, 5.4%); 
Anal., for C18H15N5O (317) Calcd./Found (%):C(68.13/68.17) 
H(4.76/4.80) N(22.07/22.10).
Synthesis of 5a,b
A solution of each of 4a,b (0.29g and 0.32g 1mmole) in 
concentrated hydrochloric acid (5 mL) and glacial acetic 
acid (5 mL) stirred in an ice bath. Sodium nitrite solution 
was added (0.14g, 2mmole) drop wise with stirring for 30 
min. The solid that formed collected by filtration, washed 
with water and dried to give the corresponding 5a,b 
respectively.
4-Phenyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine-
3-diazonium chloride (5a): Pale yellow crystals, (90%), 
m.p =160 C°,3379 (NH), 3051 (C-H, aromatic), 2132 (N≡N); 
Anal., for C17H11ClN6 (334) Calcd./Found (%): C(60.99/61.02) 
H(3.31/3.34) Cl(10.59/10.56) N(25.10/25.08). 
4 - ( 4 - M e t h o x y p h e n y l ) - 6 - ( p y r i d i n - 3 - y l ) - 1 H -
pyrazolo[3,4-b]pyridine-3-diazonium chloride (5b): Pale 
yellow crystals, (94%), m.p =330 C°, IR υ(cm-1): 3379 (NH), 
3051 (C-H, aromatic), 2132 (N≡N); Anal., for C18H13ClN6O 
(364) Calcd./Found (%): C(59.27/59.30) H(3.59/3.63) 
Cl(9.72/9.77) N(23.04/23.09).
Reaction of the diazonium chloride (5a,b) with active 
methylene (General procedure): A solution of each of 6, 
9a,b, 11a,b, 14, 17 and19 (0.113g, 0.13g, 0.1g, 0.066g, 
0.1g, 0.192g, 0.160 and 0.179g respectively, 1mmole of 
each) in ethanol (30 mL) containing 2.0g sodium acetate 
and 5a, b (0.33g and 0.36g 1mmole), the reaction mixture 
stirred at room temperature for one hour and poured 
onto ice-cold water. The formed precipitate collected by 
filtration, washed with water and dried to afford 7a, 8a,b, 
10a-d, 12a,b, 15a,b, 18a,b and 20b respectively.
Ethyl-{2-[4-Phenyl-6-(pyridin-3-yl)-2H-pyrazolo[3,4-b]
pyridin-3-yl]-hydrazinylidene}(cyano)ethanoate (7a): 
Orange crystals crystallized from ethanol (81%), m.p =300 
C°, IR υ(cm-1): 3398, 3255 (two NH ), 3054 (C-H, aromatic), 
2221 (CN), 1697 (CO); MS (m/z): 411 ( M+, 76.9% which 
corresponding to the molecular formula C22H17N7O2 of the 
assigned structure), 339 (M+-COOCH2CH3, 30.8%); 287 (M
+ 
-N=C(CN)-COOCH2CH3, 100%); 
1H NMR (δppm): 1.148 (t, 
3H, CH2CH3); 4.294 (q, 2H, CH2CH3); 7.442-8.761 (m, 9H, 
Ar and pyridinyl, H’s) 9.427 (s, 1H, C5 (H)); 12.695 (s, 1H, 
NH); 13.963 (s, 1H, NH); Anal., for C22H17N7O2 (411) Calcd./
Found(%): C(64.23/64.26) H(4.16/4.20) N(23.83/23.88).
Ethyl 4-amino-10-Phenyl-8-pyridin-3-ylpyrido[2’,3’:3,4]
pyrazolo[5,1-c][1,2,4]triazine-3-carboxylate(8a): 
Orange crystals crystallized from dioxan (86%), m.p =287 
C°, IR υ(cm-1): 3445, 3398 (NH2), 1697 (CO ester);  Anal., 
for C22H17N7O2 (411) Calcd./Found(%):C(64.23/64.18) 
H(4.15/4.20) N(23.76/23.73).
Ethyl-4-amino-10-(4-methoxyphenyl)-8-pyridin-3-
ylpyrido[2’,3’:3,4]-pyrazolo[5,1-c][1,2,4]triazine-3-
carboxylate(8b): Orange crystals crystallized from dioxan 
(86%), m.p =310 C°, IR υ(cm-1): 3407, 3254 (NH2), 1700 (CO 
ester); MS (m/z): 441 ( M+, 30.7% which corresponding to the 
molecular formula C23H19N7O3 of the assigned structure), 397 
(M+-OCH2CH3, 35.0%),  369 (M
+-COOCH2CH3, 46.9%); Anal., 
for C23H19N7O3 (441) Calcd./Found(%): C(62.58/62.62) 
H(4.34/4.37) N(22.21/22.25).
E t h y l - 4 - m e t h y l - 1 0 - p h e n y l - 8 - p y r i d i n - 3 -
ylpyrido[2’,3’:3,4]pyrazolo-[5,1-c][1,2,4]triazine-3-
carboxylate(10a): Orange crystals crystallized from dioxan 
(79%), m.p =274 C°, IR υ(cm-1): 3058 (C-H, aromatic), 1716 
(CO ester); MS (m/z): 410 ( M+, 60.8% which corresponding to 
the molecular formula C23H18N6O2 of the assigned structure), 
381 (M+-CH2CH3, 25.5%),  337 (M
+-COOCH2CH3, 46.9%); 
323 (M+- CH3,-COOCH2CH3, 9.8%);
 
  Anal., for C23H18N6O2 
(410) Calcd./Found(%):  C(67.31/67.35) H(4.42/4.46) 
N(20.48/20.52).
Ethyl-4-methyl-10-(4-methoxyphenyl)-8-pyridin-3-
ylpyrido-[2’,3’:3,4]-yrazolo[5,1-c][1,2,4]triazine-3-
carboxylate(10b): Yellow crystals crystallized from dioxan 
(80%), m.p =260 C°, IR υ(cm-1): 3051 (C-H, aromatic), 1712 
(CO); MS (m/z): 440 ( M+, 100% which corresponding to the 
molecular formula C24H20N6O3 of the assigned structure), 439 
(M+-H, 8.8%), 411 (M+-CH2CH3, 8.4%),  395 (M
+-OCH2CH3, 
9.3%),  367 (M+-COOCH2CH3, 46.8%), 353 (M
+- CH3,-
COOCH2CH3, 25.6%); 
1H NMR (δppm): 1.302 (t, 3H, J= 
7.2 Hz, CH2CH3); 1.768 (s, 3H, CH3); 3.912 (s, 3H, OCH3); 
4.531 (q, 2H, J= 7.2 Hz, CH2CH3); 7.054-8.776 (m, 8H, Ar 
and pyridinyl H’s); 9.56 (s, 1H, C9(H)); Anal., for C24H20N6O3 
(440) Calcd./Found(%):C(65.45/65.48) H(4.58/4.62) 
N(19.08/19.11).
1-(4-Methyl-10-Phenyl-8-pyridin-3-ylpyrido[2’,3’:3,4]
pyrazolo[5,1-c]-[1,2,4]triazin-3-yl)ethanone(10c): Yellow 
crystals crystallized from dioxan (77%), m.p =306 C°, IR 
υ(cm-1): 3050 (C-H, aromatic), 1699 (CO); MS (m/z): 380 
( M+, 92.2% which corresponding to the molecular formula 
C22H16N6O of the assigned structure), 337 (M
+-COCH3, 
33.3%); Anal., for C22H16N6O (380) Calcd./Found(%): 
C(69.46/69.50) H(4.24/4.29) N(22.09/22.12).
1-[10-(4-Methoxyphenyl)-4-methyl-8-pyridin-3-
ylpyrido[2’,3’:3,4]-pyrazolo[5,1-c][1,2,4]triazin-3-yl]
ethanone(10d) Yellow crystals crystallized from dioxane 
(72%), m.p = 296 C°, IR υ(cm-1): 3092 (C-H, aromatic), 1699 
(CO); MS (m/z): 411 ( M+ +H, 94.9), 367 (M+-COCH3, 40.4%); 
1H NMR (δppm): 2.906 (s, 3H, CH3); 3.218 (s, 3H, COCH3); 
3.919 (s, 3H, OCH3); 7.199-8.75 (m, 8H, Ar and pyridinyl 
H’s); 9.546 (s, 1H, C9(H)); Anal., for C23H18N6O2 (410) Calcd./
Found(%): C(67.31/67.35) H(4.42/4.47) N(20.48/20.52).
4-Amino-10-phenyl-8-pyridin-3-ylpyrido[2’,3’:3,4]
pyrazolo[5,1-c]-[1,2,4]triazine-3-carbonitrile(12a) 
Orange crystals crystallized from dioxane (89%), m.p =>330 
C°, IR υ(cm-1): 3392, 3264 (NH2), 3055 (C-H, aromatic), 
2203.0 (CN); MS (m/z): 364 (M+, 100% which corresponding 
to the molecular formula C20H12N8 of the assigned structure), 
287 (M+-C6H5, 21.7%); Anal., for C20H12N8 (364) Calcd./
Found(%):  C(65.93/65.97) H(3.32/3.36) N(30.75/30.79).
4-Amino-10- (4-methoxypheny l ) -8-pyr id in-3-
ylpyrido[2’,3’:3,4]-pyrazolo[5,1-c][1,2,4]triazine-3-
carbonitrile(12b): Orange crystals crystallized from 
dioxane (84%), m.p =>330 C°, IR υ(cm-1): 3422, 3419 
(NH2), 3066 (C-H, aromatic), 2216 (CN); MS (m/z): 394 
( M+, 36.4% which corresponding to the molecular formula 
C21H14N8O of the assigned structure), 393 (M
+-H, 18.4%); 287 
(M+-C6H4-4-OCH3, 30.6%); Anal., for C21H14N8O (394) Calcd./
Found(%):C(63.95/63.99) H(3.58/3.62) N(28.41/28.46).
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Ethyl-10,4-phenyl-8-pyridin-3-ylpyrido[2’,3’:3,4]
pyrazolo[5,1-c]-[1,2,4]triazine-3-carboxylate(15a): 
Orange crystals crystallized from dioxane (78%), m.p =310 
C°, IR υ(cm-1): 3057 (C-H, aromatic), 1736 (CO ester); 1H 
NMR (δppm): 1.059 (t, 3H, CH2CH3); 4.23 (q, 2H, CH2CH3); 
7.337-8.774 (m, 9H, Ar and pyridinyl H’s) and 9.56 (s, 
1H, C9(H)); Anal., for C28H20N6O2 (472) Calcd./Found(%): 
C(71.17/71.20) H(4.27/4.30) N(17.79/17.83).
Ethyl-10-(4-Methoxyphenyl)-4-phenyl-8-pyridin-3-
ylpyrido-[2’,3’:-3,4]pyrazolo[5,1-c][1,2,4]triazine-3-
carboxylate (15b): Yellow crystals crystallized from EtOH 
(75%), m.p =>330 C°, IR υ(cm-1): 3048 (C-H, aromatic), 
1735 (CO ester); Anal., for C29H22N6O3 (502) Calcd./
Found(%):  C(69.31/69.35) H(4.41/4.46) N(16.72/16.77).
E t h y l - 4 - o x o - 1 0 - P h e n y l - 8 - p y r i d i n - 3 - y l - 3 , 4 -
dihydropyrido[2’,3’:3,4]-pyrazolo[5,1-c][1,2,4]triazine-
3-carboxylate (18a): Yellow crystals crystallized from 
dioxane (78%), m.p = 247 C°, IR υ(cm-1): 3055 (C-
H, aromatic), 1716 (CO ester); Anal., for C22H16N6O3 
(412) Calcd./Found(%):C(64.07/64.11) H(3.91/3.95) 
N(20.38/20.41).
Ethyl-4-oxo-10-(4-Methoxyphenyl)-8-pyridin-3-yl-3,4-
dihydropyrido-[2’,3’:3,4]pyrazolo[5,1-c][1,2,4]triazine-
3-carboxylate(18b): yellow crystals crystallized from 
EtOH (86%), m.p =>330 C°, IR υ(cm-1): 3403 (OH), 1703 
(CO); MS (m/z): 425 (M+-OH, 26.4%);  Anal., for C23H18N6O4 
(442) Calcd./Found(%):C(62.44/62.49) H(4.10/4.14) 
N(19.00/19.04).
[4-Amino-10-(4-methoxyphenyl)-8-(pyridin-3-yl)
pyrido[2’,3’:3,4]-pyrazolo[5,1-c][1,2,4]triazin-3-yl]
(4-chlorophenyl)methanone (20b):  Orange crystals 
crystallized from EtOH (75%), m.p =320 C°, IR υ(cm-
1): 3365, 3204 (NH2), 3054 (C-H, aromatic) , 1655 (CO 
with H-bonding);  MS (m/z): 506 ( M+ -1H, 9.7% which 
corresponding to the molecular formula C27H18ClN7O2 of the 
assigned structure), 490 (506-NH2, 40.9%),  368 (M
+-COPhCl, 
19.9%); Anal., for C27H18ClN7O2 (507) Calcd./Found(%): 
C(63.85/63.88) H(3.57/3.60) Cl(6.98/7.02) N(19.30/19.33).
MATERIALS AND METHODS
1. Aβ42 and Aβ40 assay
Aβ42 and Aβ40 were measured in the culture medium of 
H4 cells, a human neuroglioma cell line expressing the 
double Swedish mutation (K595N/M596L) of human APP 
(APPsw). Cells were seeded onto 24-well plates (2×105 
cell well−1) and allowed to grow to confluence for 24h, in 
5% CO2/95% air in a humidified atmosphere. Increasing 
concentrations (from 3 to 300–400 µM) of the compounds 
were added to the cells overnight in a final volume of 0.5 
ml. R-flurbiprofen was used as positive control (3–1000 
µM). DMSO (1%) was used as negative control. At the end 
of the incubation, 100 µl of supernatants were removed 
and treated with a biotinylated mouse monoclonal 
antibody (4G8, Signet Laboratories Inc., Dedham, MA, 
USA), specifically recognizing the 17–24 amino acid region 
of Aβ and two rabbit polyclonal antibodies (C-term 42 
and C-term 40, BioSource International, Camarillo, CA, 
USA), specifically recognizing the C-terminus of Aβ42 
and Aβ40, respectively. Antigen-antibodies complexes 
were recognized by TAG-donkey anti-rabbit IgG (Jackson 
Immuno Research Laboratories, Soham, UK). Streptavidin 
coated magnetic beads captured the complexes and 
the signals were read by an electrochemiluminescence 
instrument (Origen M8 Analyzer, BioVeris Corporation, 
Gaithersburg, MD, USA). The cytotoxicity potential of 
test compounds was assessed in the same cells of the 
Aβ assay (H4) with the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazol-ium bromide (MTT) assay. MTT is a soluble 
pale yellow salt that is reduced by mitochondrial succinate 
dehydrogenase to form an insoluble dark blue formazan 
product to which the cell membrane is impermeable. The 
ability of cells to reduce MTT provides an indication of 
mitochondria integrity and activity and it may be interpreted 
as a measure of viability and/or cell number. After medium 
removal for of Aβ 42 and Aβ 40 determination, cells were 
incubated for 3 h with 500µl culture medium containing 0.5 
mg ml−1 MTT, at 37 ºC, 5% CO2 and saturated humidity. 
After removal of the medium, 500µl of 100% DMSO were 
added to each well. The amount of formed formazan was 
determined reading the samples at 570 nm (background 
630 nm) using a microplater reader (model 450, Bio-Rad, 
Hercules, CA, USA).
2. COX-1 and COX-2 assay
The inhibition of the cyclooxygenase activity was 
estimated measuring PGE2 production from arachidonic 
acid according o a modified version of the method26. 
Recombinant human prostaglandin H2 synthase-1 
(PGHS-1) and -2 (PGHS-2) were expressed in transfected 
Spodoptera frugiperda (Sf-9) cells (Invitrogen, San 
Diego,CA, USA). The microsomal fractions were prepared 
from the transfected cells and used to assay the enzymatic 
activities. Briefly, the enzymes (2g) reconstituted in a buffer 
(100mMTris–HCl, pH 8.0) containing 2mM phenol, were 
preincubated with vehicle (DMSO) or test compounds in 
DMSO (1%DMSO in the final assay) for 20 min at 22ºC. 
The reaction mixture was completed with 1M hematin. The 
reaction was initiated adding arachidonic acid (4 and 2 µ 
for COX-1 and COX-2, respectively) and the mixture was 
incubated for 5 min at 22ºC for COX-1 assay, or for 10 
min at 25ºC for COX-2 assay. For control measurements, 
arachidonic acid was omitted from the reaction mixture. 
The reactions were stopped by the sequential addition of 
1M HCl and 1M Tris-HCl (pH 8.0), followed by cooling to 
4ºC. The amount of PGE2 present in the reaction mixture 
was quantified using an enzyme-immunoassay.
3. Studies in Tg2576 transgenic mice
Young male and female transgenic mice (Tg2576) 
expressing the human APP gene with the Swedish double 
mutation (K670N/M671L) under the transcriptional control 
of the hamster prion protein promoter27 were used for the in 
vivo studies. Male animals were housed singly in individual 
cages while female animals were placed in groups of 3–5 
animals per cage. The experiments were performed in 
accordance with EEC Guidelines (86/609/ECC) for the use 
of laboratory animals.
3.1. Study 1
Groups of mole mice 4-5 months, each group composed 
of twenty-one male mice of 4–5 months of age were 
given by oral gavage vehicle (Kool-Aid 7.5 ml kg−1) or a 
suspension of each individual compound (100 or 300 mg 
kg−1 day−1 in Kool-Aid) once daily for 5 days. This vehicle 
was selected to replicate that reported with flurbiprofen in 
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similar studies.28-30 On day 5, mice were given a final dose 
of 100 or 300 mg kg−1 or vehicle and sacrificed 3 h later, as 
described below.
 
3.2 Study 2
Groups of female mice of 5-7 months of age, each group 
composed seventeen female mice of 5–7 months of age 
were given by oral gavage vehicle (Kool-Aid 7.5 ml kg−1) or 
a suspension of individual compound (100 or 300 mg kg−1 
day−1 in Kool-Aid) once daily for 4 days. On Day 4, mice 
were given a final dose of 100 or 300 mg kg−1 or vehicle 
and sacrificed 3 h later, as described below.
3.3 Study 3
Groups of male and female mice of 4–5 months, each 
group composed  of thirty-three male and female mice 
of 4–5 months were given vehicle or tested compounds 
or R-flurbiprofen-supplemented chow adlibitum for 4 
weeks. There were 11 animals in each treatment group. 
R-Flurbiprofen (Sigma, St. Louis, MO, USA) and the tested 
compounds were formulated into standard, color-coded, 
rodent diet by Charles River (Calco, Italy) at a final drug 
concentration of 375 ppm. The concentration of the drugs 
in the diet was the same as that used for flurbiprofen in 
previous studies.31-33 
Body weight and food consumption were monitored every 
3–4 days.
4. Plasma and brain Aβ measurements
Twenty-four hours before starting treatment, one blood 
sample was collected by means of retro-bulbar puncture 
for measurement of baseline plasma, Aβ40 and Aβ42 
concentrations. On the last day of treatment, mice were 
sacrificed by decapitation. Blood samples were collected 
in EDTA-coated tubes and centrifuged at 800 rpm for 20 
min. to separate plasma. Plasma samples were divided 
into two aliquots of approximately 100µl each and stored 
at −80 ºC until Aβ and drug assay. The brains were quickly 
removed and placed on an ice-cold plate. Cortex and 
hippocampus were dissected and immediately frozen on 
dry ice and stored at −80 ºC for Aβ assay. The remaining 
brain was immediately frozen on dry ice and stored at 
−80ºC for drug level measurements. Plasma was diluted 
1:4 for Aβ42 and 1:20 for Aβ40. For measurement of Aβ, 
brain tissue samples were homogenized in 70% formic 
acid at 1:10 (w/v). Homogenates were agitated at 4ºC for 
3 h and then centrifuged at 15,000×g for 25 min at 4ºC. 
The supernatants were collected and neutralized with 
1M Tris, pH 11 at 1:20 (w/v) dilution with 3 × protease 
inhibitor mixtures (Boehringer Mannheim, Mannheim, 
Germany). Levels of Aβ40 and Aβ42 in plasma and in brain 
homogenate supernatants were measured with commercial 
ELISA kits (The Genetics Company, Zurich, Switzerland). 
The micro-titre plates were coated with capturing purified 
monoclonal antibodies specifically recognizing the 
Cterminus of human Aβ40 (clone G2-10, reactive to amino 
acid residues 31–40, isotype IgG2b, kappa) or Aβ42 (clone 
G2-13, reactive to amino acid residues 33–42, isotype 
IgG1, kappa). As detection antibody, a monoclonal biotin 
conjugated antibody recognizing the N-terminus of human 
Aβ (clone W0-2, reactive to amino acid residues 4–10, 
isotype IgG2a, kappa) was used. The assay was linear in 
the range 25–500 pg ml−1 and the detection limit was 25 
pgml−1.
5. Plasma and brain drug measurements
Drugs levels in plasma and in brain samples were 
measured by liquid chromatography as previously 
described.34 Briefly, samples were prepared by adding 
300µl acetonitrile and 40µl phosphoric acid 40% to 100µl 
plasma or brain homogenate and placing the mixture in 
a vortex for 5 s. Plasma and brain samples were then 
centrifuged at 14,000 rpm for 5 min and the supernatants 
(15 and 50 µl, respectively) were injected into the HPLC 
system. Equipment systems with fluorescence (Waters 
474, Waters, Guyancourt, France) or mass spectrometry 
(API 2000, Applied Biosystems, Foster City, CA, USA) 
detectors were used. The chromatographic conditions 
were adapted to each compound to obtain good 
peak separation and detection sensitivity. A mixture of 
ammonium formate (20 mM) buffer–acetonitrile–methanol 
was used as mobile phase for the fluorescence detector. 
For drugs the assay was linear in the range 20–4000 ng 
g−1 in the brain and 5–1000 ng ml−1 in plasma with limits 
of quantitation of 20 ng g−1 in the brain and 5 ng ml−1 in 
plasma. For drugs, he assay was linear between 400 and 
20,000 ng g−1 in the brain and 100–8500 ng ml−1 in plasma 
with limits of quantitation of 400 ng g−1 in the brain and 100 
ng ml−1 in plasma.
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